Product INN: Mebicarum
Deva: ADAPTOL® 300 mg Tablets, ADAPTOL® 500 mg Tabletes, ADAPTOL® 300 mg Capsules
Product ATC Code: N05BX
Neuroses and neurotic disturbances (irritability, emotional excitability, anxiety, fear).
Cardialgias of different genesis, which are not connected with ischemic heart disease.
To improve tolerability of neuroleptics and tranquilizers.
Complex therapy to decrease addiction to smoking.
Product Mechanism of Action
Medicinal preparation Adaptol® active substance mebicar refer to a pharmacotherapeutic group, which is called anxiolytics.
Mebicar is proved to have anxiolytic and nootropic characteristics, it decreases unfavourable side effects caused by other tranquilizers of neuroleptic and benzodiazepine group (emotional despondency, excessive calming effect, muscles weakness), it has antialcoholic effect.
Mebicar has an effect on the structure of limbic-reticular activity, particularly on hypothalamus emotional zone, as well as on all 4 basic neuromediator systems – γ aminobutyric acid (GASS), choline -, serotonin- and adrenergic activity.
The preparation has moderate tranquilizing (anxiolytic) activity, eliminates or weakens anxiety, anxious hypochondria, fear, an internal emotional pressure and irritability. Tranquilizing effect of the preparation is not accompanied by myorelaxation and infringement of coordination of movements, it does not disturb mental or physical activity, therefore Adaptol can be administered not interrupting work or study. The preparation has no direct hypnotic effect, but it increases activity of hypnotics and normalizes duration of the disturbed night dream.
Mebicar relieves or takes off nicotine abstinence.
Alcoholic patients have a decreased level of endogen ethyl alcohol in the blood, and this is one of the reasons of inclination towards alcohol. Mebicar increases endogen alcohol level more than other tranquilizers diminishing inclination towards alcohol.
Mebicar does not cause increase of the mood or euphoria, no drug dependence or syndrome of withdrawal has been observed during its administration.
Besides nootropic activity mebicar has also nootropic characteristics. It was observed in the clinical studies that mebicar increases logic, associative thinking, improves attention and ability to work and productivity not stimulating productive symptomatics – delirium and pathologic emotional activity.
The drugs are administered orally independently of meals.
Adults use 300-500 mg 2-3 times a day. The highest single dose is 3 g, the highest daily dose - 10 g. The course of treatment - from a few days up to 2-3 months.
Complex therapy to decrease the addiction to smoking – 600-1000 mg a day for 5-6 weeks.
Elderly should not adjust the dose.
Patients with liver impairment should not diminish the dose.
Dose adjustment is not studied in patients with kidneys deficiency. These patients should use the drugs with caution.
Medicines unreasonable use is harmful to health.